A phase 1 trial of BTM-3566 in relapsed/refractory mature B cell lymphomas. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results